RT Journal Article
SR Electronic
T1 Estimating the infection fatality risk of COVID-19 in New York City, March 1–May 16, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.27.20141689
DO 10.1101/2020.06.27.20141689
A1 Yang, Wan
A1 Kandula, Sasikiran
A1 Huynh, Mary
A1 Greene, Sharon K.
A1 Van Wye, Gretchen
A1 Li, Wenhui
A1 Chan, Hiu Tai
A1 McGibbon, Emily
A1 Yeung, Alice
A1 Olson, Donald
A1 Fine, Anne
A1 Shaman, Jeffrey
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.27.20141689.abstract
AB During March 1-May 16, 2020, 191,392 laboratory-confirmed COVID-19 cases were diagnosed and reported and 20,141 confirmed and probable COVID-19 deaths occurred among New York City (NYC) residents. We applied a network model-inference system developed to support the City’s pandemic response to estimate underlying SARS-CoV-2 infection rates. Based on these estimates, we further estimated the infection fatality risk (IFR) for 5 age groups (i.e. <25, 25-44, 45-64, 65-74, and 75+ years) and all ages overall, during March 1–May 16, 2020. We estimated an overall IFR of 1.45% (95% Credible Interval: 1.09-1.87%) in NYC. In particular, weekly IFR was estimated as high as 6.1% for 65-74 year-olds and 17.0% for 75+ year-olds. These results are based on more complete ascertainment of COVID-19-related deaths in NYC and thus likely more accurately reflect the true, higher burden of death due to COVID-19 than previously reported elsewhere. It is thus crucial that officials account for and closely monitor the infection rate and population health outcomes and enact prompt public health responses accordingly as the pandemic unfolds.Competing Interest StatementJS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI. Other authors declare no conflict of interest.Funding StatementThis study was supported by the National Institute of Allergy and Infectious Diseases (AI145883), the National Science Foundation Rapid Response Research Program (RAPID; 2027369), and the NYC DOHMH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was classified as public health surveillance and exempt from ethical review and informed consent by the Institutional Review Boards of both Columbia University and New York City Department of Health and Mental Hygiene.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCOVID-19 case and mortality data for New York City publicly available from https://github.com/nychealth/coronavirus-data